Literature DB >> 26003018

Plaque Characterization to Inform the Prediction and Prevention of Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention: The CANARY Trial (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow).

Gregg W Stone1, Akiko Maehara2, James E Muller3, David G Rizik4, Kendrick A Shunk5, Ori Ben-Yehuda2, Philippe Genereux6, Ovidiu Dressler7, Rupa Parvataneni7, Sean Madden3, Priti Shah3, Emmanouil S Brilakis8, Annapoorna S Kini9.   

Abstract

OBJECTIVES: This study sought to determine whether pre-percutaneous coronary intervention (PCI) plaque characterization using near-infrared spectroscopy identifies lipid-rich plaques at risk of periprocedural myonecrosis and whether these events may be prevented by the use of a distal protection filter during PCI.
BACKGROUND: Lipid-rich plaques may be prone to distal embolization and periprocedural myocardial infarction (MI) in patients undergoing PCI.
METHODS: Patients undergoing stent implantation of a single native coronary lesion were enrolled in a multicenter, prospective trial. Near-infrared spectroscopy and intravascular ultrasound were performed at baseline, and lesions with a maximal lipid core burden index over any 4-mm length (maxLCBI4mm) ≥600 were randomized to PCI with versus without a distal protection filter. The primary endpoint was periprocedural MI, defined as troponin or a creatine kinase-myocardial band increase to 3 or more times the upper limit of normal.
RESULTS: Eighty-five patients were enrolled at 9 U.S. sites. The median (interquartile range) maxLCBI4mm was 448.4 (274.8 to 654.4) pre-PCI and decreased to 156.0 (75.6 to 312.6) post-PCI (p < 0.0001). Periprocedural MI developed in 21 patients (24.7%). The maxLCBI4mm was higher in patients with versus without MI (481.5 [425.6 to 679.6] vs. 371.5 [228.9 to 611.6], p = 0.05). Among 31 randomized lesions with maxLCBI4mm ≥600, there was no difference in the rates of periprocedural MI with versus without the use of a distal protection filter (35.7% vs. 23.5%, respectively; relative risk: 1.52; 95% confidence interval: 0.50 to 4.60, p = 0.69).
CONCLUSIONS: Plaque characterization by near-infrared spectroscopy identifies lipid-rich lesions with an increased likelihood of periprocedural MI after stent implantation, presumably due to distal embolization. However, in this pilot randomized trial, the use of a distal protection filter did not prevent myonecrosis after PCI of lipid-rich plaques.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  atherosclerosis; distal protection; embolization; myocardial infarction; near-infrared spectroscopy

Mesh:

Substances:

Year:  2015        PMID: 26003018     DOI: 10.1016/j.jcin.2015.01.032

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  21 in total

Review 1.  Optical coherence tomography-guided percutaneous coronary intervention: a review of current clinical applications.

Authors:  Kazumasa Kurogi; Masanobu Ishii; Nobuyasu Yamamoto; Kenshi Yamanaga; Kenichi Tsujita
Journal:  Cardiovasc Interv Ther       Date:  2021-01-17

Review 2.  Imaging the event-prone coronary artery plaque.

Authors:  Andreas A Giannopoulos; Dominik C Benz; Christoph Gräni; Ronny R Buechel
Journal:  J Nucl Cardiol       Date:  2017-07-06       Impact factor: 5.952

3.  Coronary plaque redistribution after stent implantation is determined by lipid composition: A NIRS-IVUS analysis.

Authors:  Tomasz Roleder; Magdalena Dobrolinska; Elzbieta Pociask; Wojciech Wanha; Grzegorz Smolka; Wojciech Walkowicz; Radoslaw Parma; Mariusz Lebek; Tomasz Bochenek; Przemysław Pietraszewski; Elvin Kedhi; Andrzej Ochala; Zbigniew Gasior; Ziad A Ali; Wojciech Wojakowski
Journal:  Cardiol J       Date:  2018-09-24       Impact factor: 2.737

Review 4.  The Role of Intracoronary Plaque Imaging with Intravascular Ultrasound, Optical Coherence Tomography, and Near-Infrared Spectroscopy in Patients with Coronary Artery Disease.

Authors:  Vu Hoang; Jill Grounds; Don Pham; Salim Virani; Ihab Hamzeh; Athar Mahmood Qureshi; Nasser Lakkis; Mahboob Alam
Journal:  Curr Atheroscler Rep       Date:  2016-09       Impact factor: 5.113

5.  The utility of total lipid core burden index/maximal lipid core burden index ratio within the culprit plaque to predict filter-no reflow: insight from near-infrared spectroscopy with intravascular ultrasound.

Authors:  Takao Sato; Yoshifusa Aizawa; Naomasa Suzuki; Yuji Taya; Sho Yuasa; Shohei Kishi; Tomoyasu Koshikawa; Koichi Fuse; Satoshi Fujita; Yoshio Ikeda; Hitoshi Kitazawa; Minoru Takahashi; Masaaki Okabe
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

6.  Long-term changes after carotid stenting assessed by intravascular ultrasound and near-infrared spectroscopy.

Authors:  Cyril Štěchovský; Petr Hájek; Robert Roland; Martin Horváth; Josef Veselka
Journal:  Cardiovasc Diagn Ther       Date:  2021-12

Review 7.  Prediction of cardiovascular outcomes by imaging coronary atherosclerosis.

Authors:  Faraz Pathan; Kazuaki Negishi
Journal:  Cardiovasc Diagn Ther       Date:  2016-08

8.  Molecular Imaging of Apoptosis in Atherosclerosis by Targeting Cell Membrane Phospholipid Asymmetry.

Authors:  Farhan Chaudhry; Hideki Kawai; Kipp W Johnson; Navneet Narula; Aditya Shekhar; Fayzan Chaudhry; Takehiro Nakahara; Takashi Tanimoto; Dongbin Kim; Matthew K M Y Adapoe; Francis G Blankenberg; Jeffrey A Mattis; Koon Y Pak; Phillip D Levy; Yukio Ozaki; Eloisa Arbustini; H William Strauss; Artiom Petrov; Valentin Fuster; Jagat Narula
Journal:  J Am Coll Cardiol       Date:  2020-10-20       Impact factor: 24.094

Review 9.  Optical Coherence Tomography of the Coronary Arteries.

Authors:  Robert Roland; Josef Veselka
Journal:  Int J Angiol       Date:  2021-02-12

Review 10.  Intracoronary Imaging in the Detection of Vulnerable Plaques.

Authors:  Jonathan A Batty; Shristy Subba; Peter Luke; Li Wing Chi Gigi; Hannah Sinclair; Vijay Kunadian
Journal:  Curr Cardiol Rep       Date:  2016-03       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.